Three Days of Remdesivir Cuts Risk for Severe COVID-19 in Outpatients
Three-day course of treatment results in reduced risk for hospitalization or death compared with placebo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.